ArticleKidney medicine2026
Refractory Chronic Kidney Disease-Associated Pruritus: Old Remedies and Novel Agents.
Article in Kidney medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Refractory chronic kidney disease associated pruritus (CKDaP) has limited therapeutic options, leading to significant distress, profound sleep disturbance, and reduced quality of life. We describe 2 cases of severe CKDaP in which conventional treatments were unsuccessful and novel therapeutic strategies were employed. The first case involves a patient receiving hemodialysis who achieved significant symptom relief with a subcutaneous lignocaine infusion, delivered using a syringe driver over 2 weeks followed by oral mexiletine. The second case concerns a kidney failure patient managed on the conservative kidney management pathway, who experienced marked improvement following weekly intravenous difelikefalin despite not receiving chronic hemodialysis. These cases underscore the challenges faced by patients and clinicians in managing severe CKDaP and its profound impact on quality of life and emotional distress. Furthermore, these cases highlight the variability in individual treatment responses and the therapeutic potential of repurposed medicines and emphasize the need for further research in this area.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.